UPDATE: Morgan Stanley Downgrades Axsome Therapeutics (AXSM) to Equalweight

Axsome Therapeutics (AXSM) PT Lowered to $25 at BofA Securities

BofA Securities analyst Ashwani Verma lowered the price target on Axsome Therapeutics (NASDAQ: AXSM) to $25.00 (from $54.00) while maintaining a Underperform rating.

Axsome Therapeutics (AXSM) PT Lowered to $162 at Ladenburg Thalmann

Ladenburg Thalmann analyst Matthew L. Kaplan lowered the price target on Axsome Therapeutics (NASDAQ: AXSM) to $162.00 (from $186.00) while maintaining a Buy rating.... More

Axsome Therapeutics (AXSM) PT Lowered to $55 at Mizuho Securities

Mizuho Securities analyst Vamil Divan lowered the price target on Axsome Therapeutics (NASDAQ: AXSM) to $55.00 (from $118.00) while maintaining a Buy rating.... More

Axsome Therapeutics's (AXSM) AXS-05 Deficiencies Set Stage for Near-Term CRL - Analyst

Earlier today, Axsome Therapeutics, Inc. (NASDAQ: AXSM) announced the results of its MERIT (Mechanistic Evaluation of Response in TRD) Phase 2 trial - a study, evaluating AXS-05, the companys investigational NMDA receptor antagonist with multimodal activity for treatment of resistant depression.

AXS-05 met both primary and secondary... More

Axsome Therapeutics (AXSM) PT Lowered to $125 at Cowen

Cowen analyst Joseph Thome lowered the price target on Axsome Therapeutics (NASDAQ: AXSM) to $125.00 (from $135.00) while maintaining a Outperform rating.

Axsome Therapeutics (AXSM) PT Lowered to $160 at Truist Securities, Following Clinical Business Update

Truist Securities analyst Joon Lee lowered the price target on Axsome Therapeutics (NASDAQ: AXSM) to $160.00 (from $200.00) while maintaining a Buy rating.

Pre-Open Stock Movers 08/09: (GNOG) (SIC) (BNTX) Higher; (ATER) (BIVI) (AXSM) Lower (more...)

Pre-Open Stock Movers

Golden Nugget Online Gaming, Inc. (Nasdaq: GNOG) 47% HIGHER; DraftKings Inc. (Nasdaq: DKNG) and Golden Nugget Online Gaming, Inc. (Nasdaq: GNOG) today announced that they have entered into a definitive agreement for DraftKings to acquire Golden Nugget Online Gaming in an all-stock transaction that has an implied equity value of approximately $1.56 billion. The acquisition will enable DraftKings to leverage Golden Nuggets well-known brand, iGaming product experience and existing combined database of more than 5 million customers. In... More

Axsome Therapeutics (AXSM) Announces AXS-05 Achieves Primary and Key Secondary Endpoints in the MERIT Phase 2 Trial in Treatment Resistant Depression

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that AXS-05, a novel, oral, investigational NMDA receptor antagonist with multimodal activity, met the primary and key secondary endpoints in the MERIT (Mechanistic Evaluation of Response in TRD) Phase 2 trial, and substantially and statistically significantly prevented relapse of depressive symptoms compared to placebo in patients with treatment resistant depression (TRD). The MERIT study was a randomized, double-blind, placebo-controlled, relapse prevention, multi-center, U.S. trial, which evaluated 44 TRD patients. Patients in stable remission... More